Non-Hodgkin Lymphoma

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy was confirmed to induce durable responses and a clinically meaningful overall survival benefit in patients with relapsed/refractory diffuse large B-cell lymphoma.

Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.

Single-agent selinexor was found to induce durable responses with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma who had received at least 2 prior lines of chemoimmunotherapy.

The FDA has cleared an investigational new drug application for the first-of-its-kind, off-the-shelf CAR T-cell product FT819, which targets CD19-positive malignancies.

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

Ian W. Flinn, MD, PhD, discusses the adverse effects associated with BTK inhibitors in B-cell malignancies, as well as the design of an ongoing phase 2 study with zanubrutinib.